IL3 and acute myeloid leukemia: In line with this idea, SL401 (tagraxofusp), a recombinant protein made of IL-3 fused to diphtheria toxin (already approved in 2018 for the use in BPDCN) [18], showed some promising results in a series of CD123+ AML/MDS patients [19,20].